Immunotherapy duo takes on cervical cancer in new trial
NCT ID NCT06715241
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding relatlimab to nivolumab (both immunotherapy drugs) works better than nivolumab alone for locally advanced cervical cancer. About 77 women with stage IIB to IVA cervical cancer will receive either the combination or nivolumab alone before standard chemoradiation. The main goal is to see how many tumors shrink after six weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
relatlimab and nivolumab (immunotherapy drugs)
What this could lead to
If successful, this could point toward a more effective immunotherapy option for locally advanced cervical cancer, potentially improving tumor shrinkage before standard treatment.
What could go wrong
This is an early Phase 2 trial with only 77 participants, designed to 'seek a signal' rather than prove benefit. The combination may cause more side effects than nivolumab alone, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Besançon - Hôpital Jean Minjoz
Besançon, 25030, France
-
CHRU Lille - Hôpital Jeanne de Flandre
Lille, 59000, France
-
CHU STRASBOURG - Hôpital de Hautepierre
Strasbourg, France
-
CHU Saint-Etienne - Pôle de Cancérologie
Saint-Etienne, 42271, France
-
CHU de BREST - Hôpital Cavale Blanche
Brest, 29200, France
-
CHU de Dijon
Dijon, 21079, France
-
CHU de Limoges - Hôpital Dupuytren
Limoges, 87042, France
-
CHU de Poitiers - Hôpital de la Milétrie
Poitiers, 86021, France
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre CARIO - HPCA
Plérin, 22190, France
-
Centre Eugène Marquis
Rennes, 35042, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Hospitalier Intercommunal de Créteil
Créteil, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
-
Centre Jean Perrin
Clermont-Ferrand, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, France
-
Groupe Hospitalier Diaconesses - Croix Saint-Simon
Paris, 75012, France
-
Gustave Roussy
Villejuif, 94805, France
-
ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, 67200, France
-
ICL - Centre Alexis Vautrin
Vandœuvre-lès-Nancy, 54519, France
-
ICO - Centre René Gauducheau
Saint-Herblain, 44805, France
-
ICO Paul Papin
Angers, 49055, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Curie
Paris, 75005, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Oncopole Claudius Regaud
Toulouse, 31059, France
-
Recherche Oncologique Clinique 37 (ROC 37)
Tours, 37170, France
-
Sainte-Catherine Institut du Cancer Avignon-Provence
Avignon, 84918, France
-
Dijon, France